FeesSafety
Pluang+

onsemi Q3 2026 revenue rises 11%, EPS up 40%, driven by AI data center growth and strategic acquisitions

Company Fundamentals
02 Nov 2026, 23:10 WIB
GlobeNewsWire
View Source
Bullish
onsemi Q3 2026 revenue rises 11%, EPS up 40%, driven by AI data center growth and strategic acquisitions

onsemi reported strong Q3 2026 results with revenue increasing 11% year-over-year to $1.72 billion and earnings per share growing over 40% to $0.79 GAAP and $0.90 non-GAAP. The company highlighted a 175% year-over-year surge in AI data center revenue and expanded gross margins to 41.4%. Strategic moves include acquiring Ferric to boost AI processor power delivery and revising terms for Synaptics acquisition, positioning onsemi for sustained profitable growth. The company projects continued strong performance into Q4 2026 with revenue guidance of $1.715-$1.815 billion and expanding margins.

Onsemi's Q3 2026 results provide context for technology sector performance. For readers following this sector, here is Pluang's market snapshot as of Nov 03, 2026 02:11 WIB: out of 150 priced Technology-sector US stocks, 62 rose and 86 fell. Notable movers include MRVL at USD 174.00 with a 1-day change of -11.41%, BTDR at USD 6.07 down 9.54%, and FSLY at USD 20.99 down 9.19%.

More News

Federal Home Loan Bank of Atlanta elects new directors and appoints 2027 Chair and Vice Chair.

Federal Home Loan Bank of Atlanta elects new directors and appoints 2027 Chair and Vice Chair.

The Federal Home Loan Bank of Atlanta announced the election of three new member directors and the re-election of one independent director to its board for 2026. Suzanne DeFerie was named Chair and Kathy McKinney Vice Chair for 2027, ensuring experie...

Neutral
1 hour ago
Exosens reports 50.9M shares and 59.1M voting rights as of October 31, 2026

Exosens reports 50.9M shares and 59.1M voting rights as of October 31, 2026

Exosens disclosed its monthly update on the total number of shares and voting rights in its share capital as of October 31, 2026. The company has 50,936,749 shares outstanding, with 59,162,039 exercisable voting rights after deducting treasury shares...

Company Fundamentals
Neutral
4 hours ago
Exosens reports total shares and voting rights as of October 31, 2026, confirming capital structure details.

Exosens reports total shares and voting rights as of October 31, 2026, confirming capital structure details.

Exosens has released its monthly update on the total number of shares and voting rights composing its capital as of October 31, 2026. The company reports 50,936,749 total shares and 59,425,768 theoretical voting rights, with 59,162,039 exercisable vo...

Company Fundamentals
Neutral
4 hours ago
Phase 2 trial shows REC-4881 cuts polyp burden in FAP patients with durable effects and good safety.

Phase 2 trial shows REC-4881 cuts polyp burden in FAP patients with durable effects and good safety.

Recursion Pharmaceuticals announced positive Phase 2 results for REC-4881, an oral MEK1/2 inhibitor, in treating familial adenomatous polyposis (FAP). The TUPELO trial showed a 47% median reduction in total polyp burden after 12 weeks of treatment, w...

Company Fundamentals
Bullish
5 hours ago
Vornado reports Q3 2026 net loss of $47M but FFO rises to $0.65 per share, announces major 350 Park Ave joint venture.

Vornado reports Q3 2026 net loss of $47M but FFO rises to $0.65 per share, announces major 350 Park Ave joint venture.

Vornado Realty Trust reported a net loss of $47.1 million for Q3 2026, a decline from net income of $11.6 million in the prior year period, primarily due to a large gain in 2025 related to a master lease. However, funds from operations (FFO) increase...

Company Fundamentals
Bearish
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App